These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29679282)

  • 21. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
    Huynh C; Gillis A; Fazendin J; Abdullatif H
    Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
    Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
    J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Burosumab in X-linked hypophosphatemia: a profile of its use in the USA.
    Lyseng-Williamson KA
    Drugs Ther Perspect; 2018; 34(11):497-506. PubMed ID: 30459508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial.
    Fratzl-Zelman N; Hartmann MA; Gamsjaeger S; Rokidi S; Paschalis EP; Blouin S; Zwerina J
    J Bone Miner Res; 2022 Sep; 37(9):1665-1678. PubMed ID: 35775373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
    Filler G; Tremblay O; Chen E; Huang SSH; Stein R
    Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
    Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
    Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations.
    Padidela R; Cheung MS; Saraff V; Dharmaraj P
    Endocr Connect; 2020 Oct; 9(10):1051-1056. PubMed ID: 33112809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description.
    Brandi ML; Ariceta G; Beck-Nielsen SS; Boot AM; Briot K; de Lucas Collantes C; Emma F; Giannini S; Haffner D; Keen R; Levtchenko E; Mӓkitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Mughal MZ
    Ther Adv Chronic Dis; 2022; 13():20406223221117471. PubMed ID: 36082134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives.
    Raimann A; Mindler GT; Kocijan R; Bekes K; Zwerina J; Haeusler G; Ganger R
    Wien Med Wochenschr; 2020 Apr; 170(5-6):116-123. PubMed ID: 31993875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
    Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
    Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
    Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
    Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
    Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
    Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
    Perwad F; Portale AA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
    [No Abstract]   [Full Text] [Related]  

  • 39. Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia.
    Lee SK; Gosselin NH; Taylor J; Roberts MS; McKeever K; Shi J
    J Clin Pharmacol; 2022 Jan; 62(1):87-98. PubMed ID: 34352114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
    Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.